It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Moleculin Biotech, Inc.'s (NASDAQ:MBRX) case, it's fantastic news for shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Moleculin Biotech Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Co-Founder Walter Klemp bought US$250k worth of shares at a price of US$0.37 per share. That means that even when the share price was higher than US$0.35 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Moleculin Biotech insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

See our latest analysis for Moleculin Biotech

Moleculin Biotech is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insiders At Moleculin Biotech Have Bought Stock Recently

Over the last quarter, Moleculin Biotech insiders have spent a meaningful amount on shares. Overall, two insiders shelled out US$350k for shares in the company -- and none sold. This is a positive in our book as it implies some confidence.

Does Moleculin Biotech Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Moleculin Biotech insiders own 4.3% of the company, worth about US$338k. We consider this fairly low insider ownership.

So What Do The Moleculin Biotech Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Moleculin Biotech insiders are expecting a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 5 warning signs we've spotted with Moleculin Biotech (including 4 which are concerning).

Of course Moleculin Biotech may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.